Purchases and Sales Made in Q3 2022 in Biohaven Pharmaceutical Holding CO Ltd. (BHVN)
This table provides information about the institutional ownership of Biohaven Pharmaceutical Holding CO Ltd. (BHVN) during Q3 2022. The information is specifically focused on institutions that hold shares of Biohaven Pharmaceutical Holding Co Ltd..
Report Date | Institution (Fund) | Operation | Option | Shares change | Value Range | Shares Held | Trade History |
---|---|---|---|---|---|---|---|
Nov 14, 2022
Q3 2022
|
Charles Schwab Investment Management Inc
San Francisco, CA |
SELL
|
- |
-138K- 22.01% |
$20M - $21M
|
489K
$15.1M
|
|
Nov 10, 2022
Q3 2022
|
Gabelli Funds LLC
Rye, NY |
SELL
|
- |
-157K- 74.58% |
$22.7M - $23.9M
|
53.5K
$1.66M
|
|
Nov 14, 2022
Q3 2022
|
Price T Rowe Associates Inc
Baltimore, MD |
SELL
|
- |
-165K- 31.7% |
$24M - $25.2M
|
356K
$11M
|
|
Nov 01, 2022
Q3 2022
|
Rice Hall James & Associates, LLC
|
SELL
|
- |
-181K- 68.78% |
$26.2M - $27.6M
|
82.1K
$2.54M
|
|
Nov 14, 2022
Q3 2022
|
Magnetar Financial LLC
Evanston, IL |
SELL
|
- |
-228K- 38.54% |
$33M - $34.7M
|
363K
$11.3M
|
|
Nov 14, 2022
Q3 2022
|
Pentwater Capital Management LP
Naples, FL |
SELL
|
- |
-267K- 18.67% |
$38.7M - $40.7M
|
1.16M
$36M
|
|
Nov 14, 2022
Q3 2022
|
Ubs Asset Management Americas Inc
Chicago, IL |
SELL
|
- |
-275K- 81.11% |
$39.8M - $41.8M
|
64K
$1.98M
|
|
Nov 14, 2022
Q3 2022
|
Man Group PLC
London, X0 |
SELL
|
- |
-398K- 91.25% |
$57.6M - $60.6M
|
38.1K
$1.18M
|
|
Nov 14, 2022
Q3 2022
|
Janus Henderson Group PLC
London, X0 |
SELL
|
- |
-526K- 48.89% |
$76.2M - $80.1M
|
550K
$17M
|
|
Nov 14, 2022
Q3 2022
|
Orbimed Advisors LLC
San Diego, CA |
SELL
|
- |
-548K- 76.25% |
$79.5M - $83.5M
|
171K
$5.29M
|
|
Oct 26, 2022
Q3 2022
|
Allspring Global Investments Holdings, LLC
|
SELL
|
- |
-624K- 68.45% |
$90.4M - $95M
|
287K
$8.9M
|
|
Nov 14, 2022
Q3 2022
|
Adage Capital Partners Gp, L.L.C.
Boston, MA |
SELL
|
- |
-731K- 24.06% |
$106M - $111M
|
2.31M
$71.5M
|
|
Nov 14, 2022
Q3 2022
|
Capital World Investors
Los Angeles, CA |
SELL
|
- |
-1.8M- 68.14% |
$261M - $274M
|
842K
$26.1M
|
|
Nov 14, 2022
Q3 2022
|
Marshall Wace, LLP
London, X0 |
SELL
|
- |
-1.91M- 98.99% |
$277M - $291M
|
19.4K
$601K
|